GM2 Gangliosidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
GM2 gangliosidosis is an autosomal recessive metabolic disorder due to β-hexosaminidase deficiency. GM2 gangliosidosis is divided into three clinical subtypes according to the age at onset. In general, the later the disease occurs, the more slowly it progresses. Type 1 (infantile type) begins in the first year of life with rapidly progressive diffuse neurological deterioration and death before four years of age. GM2 gangliosidosis is caused by deficiency of (beta-1,4 N-acetyl galactosaminidase) hexosaminidase activity. The two isoenzymes are called hexosaminidase A and B. Typical infantile forms of GM2 gangliosidosis are Tay–Sachs disease and Sandhoff disease.
·
The incidence of the Tay Sachs variant in the
general population is estimated to be 1.75 cases per 250,000 live births.
However, Sandhoff-variant incidence has been reported at 1 to 2 cases per
350,000 patients.
·
The most common initial symptoms were
developmental arrest (83%), abnormal startle response (65%), and low muscle
tone (60%).
Thelansis’s “GM2 Gangliosidosis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential GM2
Gangliosidosis treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of GM2 Gangliosidosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
GM2 Gangliosidosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment